×
About 214,056 results

ALLMedicine™ Cardiovascular Disease Center

Research & Reviews  99,407 results

Impact of Preinfection Left Ventricular Ejection Fraction on Outcomes in COVID-19 Infec...
https://doi.org/10.1016/j.cpcardiol.2021.100845
Current Problems in Cardiology; Morin DP, Manzo MA et. al.

May 17th, 2021 - Coronavirus disease 2019 (COVID-19) has high infectivity and causes extensive morbidity and mortality. Cardiovascular disease is a risk factor for adverse outcomes in COVID-19, but baseline left ventricular ejection fraction (LVEF) in particular h...

Predictors of Obstructive Sleep Apnoea (OSA) Population in the Coronary Angiogram Datab...
https://doi.org/10.1016/j.cpcardiol.2021.100846
Current Problems in Cardiology; Ooi EL, Rajendran S et. al.

May 17th, 2021 - Obstructive sleep apnoea (OSA) is increasingly recognized to be a risk factor for cardiovascular disease. This study assessed the prevalence and clinical predictors of OSA in patients undergoing coronary angiography. Consecutive patients undergoin...

Cardiovascular Outcomes With Anti-Inflammatory Therapies: Review of Literature.
https://doi.org/10.1016/j.cpcardiol.2021.100840
Current Problems in Cardiology; Abdelmaseih R, Alsamman MM et. al.

May 17th, 2021 - Inflammation is a major contributing factor in the development of cardiovascular disease (CVD) and has been a popular topic of discussion as it provides a potential therapeutic target to reduce disease progression. Multiple inflammatory markers ha...

Does rearranging meal times at night improve cardiovascular risk factors? An Australian...
https://doi.org/10.1016/j.numecd.2021.03.008
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Leung GKW, Davis R et. al.

May 17th, 2021 - Shift workers face an increased risk of cardiovascular disease (CVD), type-2 diabetes and obesity. Eating during the night is a likely contributing factor, as it coincides with the time at which postprandial metabolism is least efficient. In this ...

Plasma S1P (Sphingosine-1-Phosphate) Links to Hypertension and Biomarkers of Inflammati...
https://doi.org/10.1161/HYPERTENSIONAHA.120.17379
Hypertension (Dallas, Tex. : 1979); Jujic A, Matthes F et. al.

May 17th, 2021 - S1P (Sphingosine-1-phosphate) is an important regulator of immune cell trafficking and vascular dysfunction contributing to the development and progression of overt hypertension. Although targeting S1P signaling revealed therapeutic potential in d...

see more →

Guidelines  605 results

Lower- and higher-dose aspirin achieve similar protection and safety for people with cardiovascular disease
https://www.pcori.org/news-release/lower-higher-dose-aspirin-achieve-similar-protection-and-safety-cardiovascular-disease-adaptable
PCORI Patient-Centered Outcomes Research Institute;

May 14th, 2021 - WASHINGTON, DC—People with cardiovascular disease (CVD) taking aspirin to lower their chances of suffering a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization for heart attack and stroke, wheth...

Pragmatic Trials — Need for ADAPTABLE Design
https://www.nejm.org/doi/full/10.1056/NEJMe2106430?query=recirc_curatedRelated_article
New England Journal of Medicine; Baigent C.

May 14th, 2021 - The publication in the Journal of the results of ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)1 comparing two doses of aspirin for the secondary prevention of cardiovascular disease represents a...

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa2102137?query=featured_home
New England Journal of Medicine; Jones WS, Mulder H et. al.

May 14th, 2021 - BACKGROUND The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy.

Central and peripheral arterial diseases in chronic kidney disease: conclusions from a ...
https://doi.org/10.1016/j.kint.2021.04.029
Kidney International; Johansen KL, Garimella PS et. al.

May 7th, 2021 - Chronic kidney disease (CKD) affects about 10% of all populations worldwide, with about 2 million people requiring dialysis. Although patients with CKD are at high risk of cardiovascular disease and events, they are often underrepresented or exclu...

Alcohol in Moderation May Help the Heart by Calming Stress Signals in the Brain
https://www.acc.org/about-acc/press-releases/2021/05/05/19/14/alcohol-in-moderation-may-help-the-heart-by-calming-stress-signals-in-the-brain
The American College of Cardiology;

May 5th, 2021 - WASHINGTON (May 06, 2021) - Moderate alcohol intake—defined as no more than one alcoholic drink for women and two for men per day—has been associated with a lower risk of dying from cardiovascular disease when compared with individuals who abstain...

see more →

Drugs  349 results see all →

Clinicaltrials.gov  105,723 results

Impact of Preinfection Left Ventricular Ejection Fraction on Outcomes in COVID-19 Infec...
https://doi.org/10.1016/j.cpcardiol.2021.100845
Current Problems in Cardiology; Morin DP, Manzo MA et. al.

May 17th, 2021 - Coronavirus disease 2019 (COVID-19) has high infectivity and causes extensive morbidity and mortality. Cardiovascular disease is a risk factor for adverse outcomes in COVID-19, but baseline left ventricular ejection fraction (LVEF) in particular h...

Predictors of Obstructive Sleep Apnoea (OSA) Population in the Coronary Angiogram Datab...
https://doi.org/10.1016/j.cpcardiol.2021.100846
Current Problems in Cardiology; Ooi EL, Rajendran S et. al.

May 17th, 2021 - Obstructive sleep apnoea (OSA) is increasingly recognized to be a risk factor for cardiovascular disease. This study assessed the prevalence and clinical predictors of OSA in patients undergoing coronary angiography. Consecutive patients undergoin...

Cardiovascular Outcomes With Anti-Inflammatory Therapies: Review of Literature.
https://doi.org/10.1016/j.cpcardiol.2021.100840
Current Problems in Cardiology; Abdelmaseih R, Alsamman MM et. al.

May 17th, 2021 - Inflammation is a major contributing factor in the development of cardiovascular disease (CVD) and has been a popular topic of discussion as it provides a potential therapeutic target to reduce disease progression. Multiple inflammatory markers ha...

Does rearranging meal times at night improve cardiovascular risk factors? An Australian...
https://doi.org/10.1016/j.numecd.2021.03.008
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Leung GKW, Davis R et. al.

May 17th, 2021 - Shift workers face an increased risk of cardiovascular disease (CVD), type-2 diabetes and obesity. Eating during the night is a likely contributing factor, as it coincides with the time at which postprandial metabolism is least efficient. In this ...

Plasma S1P (Sphingosine-1-Phosphate) Links to Hypertension and Biomarkers of Inflammati...
https://doi.org/10.1161/HYPERTENSIONAHA.120.17379
Hypertension (Dallas, Tex. : 1979); Jujic A, Matthes F et. al.

May 17th, 2021 - S1P (Sphingosine-1-phosphate) is an important regulator of immune cell trafficking and vascular dysfunction contributing to the development and progression of overt hypertension. Although targeting S1P signaling revealed therapeutic potential in d...

see more →

News  7,951 results

CT Scans for Breast Cancer Radiotherapy Also Show Cardiovascular Risk
https://www.medscape.com/viewarticle/951150

May 16th, 2021 - NEW YORK (Reuters Health) - Coronary-artery calcium (CAC) measured automatically on radiotherapy-planning CT scans in women being treated for breast cancer may be used to spot those at increased risk for cardiovascular disease, researchers say. "W...

Commission Outlines Plan for Global Fight Against CVD in Women
https://www.medscape.com/viewarticle/951246

May 15th, 2021 - An expert panel convened by The Lancet calls for urgent action to reduce the global burden of cardiovascular disease (CVD) in women and has outlined an ambitious agenda to accomplish that goal. The report, from the all-female-led Lancet Women and ...

Lower- and higher-dose aspirin achieve similar protection and safety for people with cardiovascular disease
https://www.pcori.org/news-release/lower-higher-dose-aspirin-achieve-similar-protection-and-safety-cardiovascular-disease-adaptable
PCORI Patient-Centered Outcomes Research Institute;

May 14th, 2021 - WASHINGTON, DC—People with cardiovascular disease (CVD) taking aspirin to lower their chances of suffering a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization for heart attack and stroke, wheth...

Pragmatic Trials — Need for ADAPTABLE Design
https://www.nejm.org/doi/full/10.1056/NEJMe2106430?query=recirc_curatedRelated_article
New England Journal of Medicine; Baigent C.

May 14th, 2021 - The publication in the Journal of the results of ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)1 comparing two doses of aspirin for the secondary prevention of cardiovascular disease represents a...

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa2102137?query=featured_home
New England Journal of Medicine; Jones WS, Mulder H et. al.

May 14th, 2021 - BACKGROUND The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy.

see more →

Patient Education  21 results see all →